Search Results - "Armand, Philippe"

Immune checkpoint blockade in hematologic malignancies by Armand, Philippe

“…Therapeutic blockade of immune checkpoint pathways, in particular cytotoxic T-lymphocyte associated protein 4 and programmed-death 1 (PD-1), has become a…”
Get full text

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course by Nishino, Mizuki, Ramaiya, Nikhil H, Awad, Mark M, Sholl, Lynette M, Maattala, Jennifer A, Taibi, Myriam, Hatabu, Hiroto, Ott, Patrick A, Armand, Philippe F, Hodi, F Stephen

“…Investigate the clinical characteristics, radiographic patterns, and treatment course of PD-1 inhibitor-related pneumonitis in advanced cancer patients. Among…”
Get full text

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy by Cheson, Bruce D., Ansell, Stephen, Schwartz, Larry, Gordon, Leo I., Advani, Ranjana, Jacene, Heather A., Hoos, Axel, Barrington, Sally F., Armand, Philippe

“…Uniformly adopted response criteria are essential for assessment of therapies incorporating conventional chemotherapy and chemoimmunotherapy regimens…”
Get full text

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma by Chen, Robert, Zinzani, Pier Luigi, Fanale, Michelle A, Armand, Philippe, Johnson, Nathalie A, Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P, Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A, Zhang, Yinghua, Ricart, Alejandro D, Balakumaran, Arun, Moskowitz, Craig H

“…Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2…”
Get full text

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial by Armand, Philippe, Engert, Andreas, Younes, Anas, Fanale, Michelle, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M, Collins, Graham P, Ramchandren, Radhakrishnan, Cohen, Jonathon B, De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J, Trneny, Marek, Shipp, Margaret A, Kato, Kazunobu, Sumbul, Anne, Farsaci, Benedetto, Ansell, Stephen M

“…Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed…”
Get full text

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 by Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun, Moskowitz, Craig H.

“…Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the…”
Get full text

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study by Ansell, Stephen M, Minnema, Monique C, Johnson, Peter, Timmerman, John M, Armand, Philippe, Shipp, Margaret A, Rodig, Scott J, Ligon, Azra H, Roemer, Margaretha G M, Reddy, Nishitha, Cohen, Jonathon B, Assouline, Sarit, Poon, Michelle, Sharma, Manish, Kato, Kazunobu, Samakoglu, Selda, Sumbul, Anne, Grigg, Andrew

“…Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1…”
Get full text

Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil by Herbaux, Charles, Merryman, Reid, Devine, Steven, Armand, Philippe, Houot, Roch, Morschhauser, Franck, Haverkos, Bradley

“…PD-1 blockade is an effective therapy in relapsed/refractory (R/R) classical Hodgkin Lymphoma (cHL) who have relapsed after or are ineligible for autologous…”
Get full text

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome by Roemer, Margaretha G M, Advani, Ranjana H, Ligon, Azra H, Natkunam, Yasodha, Redd, Robert A, Homer, Heather, Connelly, Courtney F, Sun, Heather H, Daadi, Sarah E, Freeman, Gordon J, Armand, Philippe, Chapuy, Bjoern, de Jong, Daphne, Hoppe, Richard T, Neuberg, Donna S, Rodig, Scott J, Shipp, Margaret A

“…Classical Hodgkin lymphomas (cHLs) include small numbers of malignant Reed-Sternberg cells within an extensive but ineffective inflammatory/immune cell…”
Get full text

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation by Armand, Philippe, Kim, Haesook T., Logan, Brent R., Wang, Zhiwei, Alyea, Edwin P., Kalaycio, Matt E., Maziarz, Richard T., Antin, Joseph H., Soiffer, Robert J., Weisdorf, Daniel J., Rizzo, J. Douglas, Horowitz, Mary M., Saber, Wael

“…Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able…”
Get full text

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity by Jacobson, Caron A, Hunter, Bradley D, Redd, Robert, Rodig, Scott J, Chen, Pei-Hsuan, Wright, Kyle, Lipschitz, Mikel, Ritz, Jerome, Kamihara, Yusuke, Armand, Philippe, Nikiforow, Sarah, Rogalski, Michael, Maakaron, Joseph, Jaglowski, Samantha, Maus, Marcela V, Chen, Yi-Bin, Abramson, Jeremy S, Kline, Justin, Budde, Elizabeth, Herrera, Alex, Mei, Matthew, Cohen, Jonathon B, Smith, Stephen D, Maloney, David G, Gopal, Ajay K, Frigault, Matthew J, Acharya, Utkarsh H

“…Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of…”
Get full text

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial by Younes, Anas, Prof, Santoro, Armando, Prof, Shipp, Margaret, Prof, Zinzani, Pier Luigi, Prof, Timmerman, John M, MD, Ansell, Stephen, Prof, Armand, Philippe, MD, Fanale, Michelle, MD, Ratanatharathorn, Voravit, MD, Kuruvilla, John, MD, Cohen, Jonathon B, MD, Collins, Graham, MD, Savage, Kerry J, MD, Trneny, Marek, Prof, Kato, Kazunobu, MD, Farsaci, Benedetto, MD, Parker, Susan M, PhD, Rodig, Scott, MD, Roemer, Margaretha G M, MS, Ligon, Azra H, PhD, Engert, Andreas, Prof

“…Summary Background Malignant cells of classical Hodgkin's lymphoma are characterised by genetic alterations at the 9p24.1 locus, leading to overexpression of…”
Get full text

Observed controls on resilience of groundwater to climate variability in sub-Saharan Africa by Cuthbert, Mark O., Taylor, Richard G., Favreau, Guillaume, Todd, Martin C., Shamsudduha, Mohammad, Villholth, Karen G., MacDonald, Alan M., Scanlon, Bridget R., Kotchoni, D. O. Valerie, Vouillamoz, Jean-Michel, Lawson, Fabrice M. A., Adjomayi, Philippe Armand, Kashaigili, Japhet, Seddon, David, Sorensen, James P. R., Ebrahim, Girma Yimer, Owor, Michael, Nyenje, Philip M., Nazoumou, Yahaya, Goni, Ibrahim, Ousmane, Boukari Issoufou, Sibanda, Tenant, Ascott, Matthew J., Macdonald, David M. J., Agyekum, William, Koussoubé, Youssouf, Wanke, Heike, Kim, Hyungjun, Wada, Yoshihide, Lo, Min-Hui, Oki, Taikan, Kukuric, Neno

“…Groundwater in sub-Saharan Africa supports livelihoods and poverty alleviation 1 , 2 , maintains vital ecosystems, and strongly influences terrestrial water…”
Get full text

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study by Ramchandren, Radhakrishnan, Domingo-Domènech, Eva, Rueda, Antonio, Trněný, Marek, Feldman, Tatyana A, Lee, Hun Ju, Provencio, Mariano, Sillaber, Christian, Cohen, Jonathon B, Savage, Kerry J, Willenbacher, Wolfgang, Ligon, Azra H, Ouyang, Jing, Redd, Robert, Rodig, Scott J, Shipp, Margaret A, Sacchi, Mariana, Sumbul, Anne, Armand, Philippe, Ansell, Stephen M

“…Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma…”
Get full text

PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD by Haverkos, Bradley M., Abbott, Diana, Hamadani, Mehdi, Armand, Philippe, Flowers, Mary E., Merryman, Reid, Kamdar, Manali, Kanate, Abraham Sebastian, Saad, Ayman, Mehta, Amitkumar, Ganguly, Siddhartha, Fenske, Timothy S., Hari, Parameswaran, Lowsky, Robert, Andritsos, Leslie, Jagasia, Madan, Bashey, Asad, Brown, Stacey, Bachanova, Veronika, Stephens, Deborah, Mineishi, Shin, Nakamura, Ryotaro, Chen, Yi-Bin, Blazar, Bruce R., Gutman, Jonathan, Devine, Steven M.

“…Given the limited treatment options for relapsed lymphoma post–allogeneic hematopoietic cell transplantation (post–allo-HCT) and the success of programmed…”
Get full text

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity by Lampson, Benjamin L., Kasar, Siddha N., Matos, Tiago R., Morgan, Elizabeth A., Rassenti, Laura, Davids, Matthew S., Fisher, David C., Freedman, Arnold S., Jacobson, Caron A., Armand, Philippe, Abramson, Jeremy S., Arnason, Jon E., Kipps, Thomas J., Fein, Joshua, Fernandes, Stacey, Hanna, John, Ritz, Jerome, Kim, Haesook T., Brown, Jennifer R.

“…Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). To…”
Get full text

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma by Armand, Philippe, Janssens, Ann, Gritti, Giuseppe, Radford, John, Timmerman, John, Pinto, Antonio, Mercadal Vilchez, Santiago, Johnson, Peter, Cunningham, David, Leonard, John P., Rodig, Scott J., Martín-Regueira, Patricia, Sumbul, Anne, Samakoglu, Selda, Tang, Hao, Ansell, Stephen M.

“…Nivolumab, an anti–programmed death-1 (PD-1) monoclonal antibody, showed promising activity in relapsed or refractory (R/R) follicular lymphoma (FL) in a phase…”
Get full text

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease by Koreth, John, Kim, Haesook T., Jones, Kyle T., Lange, Paulina B., Reynolds, Carol G., Chammas, Marie J., Dusenbury, Katherine, Whangbo, Jennifer, Nikiforow, Sarah, Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Chen, Yi-Bin, Avigan, David, Blazar, Bruce R., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J.

“…Chronic graft-versus-host disease (cGVHD) is associated with inadequate reconstitution of tolerogenic CD4+CD25+FOXP3+ regulatory T cells (Tregs). Previous…”
Get full text

A disease risk index for patients undergoing allogeneic stem cell transplantation by Armand, Philippe, Gibson, Christopher J., Cutler, Corey, Ho, Vincent T., Koreth, John, Alyea, Edwin P., Ritz, Jerome, Sorror, Mohamed L., Lee, Stephanie J., Deeg, H. Joachim, Storer, Barry E., Appelbaum, Frederick R., Antin, Joseph H., Soiffer, Robert J., Kim, Haesook T.

“…The outcome of allogeneic HSCT varies considerably by the disease and remission status at the time of transplantation. Any retrospective or prospective HSCT…”
Get full text

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation by Davids, Matthew S., Kim, Haesook T., Costello, Caitlin, Herrera, Alex F., Locke, Frederick L., Maegawa, Rodrigo O., Savell, Alexandra, Mazzeo, Michael, Anderson, Adrienne, Boardman, Alexander P., Weber, Augustine, Avigan, David, Chen, Yi-Bin, Nikiforow, Sarah, Ho, Vincent T., Cutler, Corey, Alyea, Edwin P., Bachireddy, Pavan, Wu, Catherine J., Ritz, Jerome, Streicher, Howard, Ball, Edward D., Bashey, Asad, Soiffer, Robert J., Armand, Philippe

“…Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs-tumor effects following allogeneic hematopoietic cell…”
Get full text